Call to order
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): (Part 1 of 2) a. Androgenic agents b. Antibiotics, gastrointestinal (GI) c. Antibiotics, topical d. Antibiotics, vaginal
Consideration of minutes from July 23, 2021 (vote required)
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): e. Anticonvulsants f. Antiemetics/Antivertigo agents g. Antifungals, oral h. Antifungals, topical i. Antihistamines - first generation j. Antiparasitics, topical k. Antipsychotics l. Antivirals, topical m. Bone resorption suppression and related agents n. Colony stimulating factors o. Epinephrine, self-injected p. GI Motility, chronic q. Growth hormone r. Hepatitis C s. HIV / AIDS t. Hypoglycemics, insulin and related agents u. Hypoglycemics, meglitinides v. Hypoglycemics, metformin w. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2) inhibitors x. Hypoglycemics, thiazolidinediones (TZDs) y. Macrolides-Ketolides z. Opiate dependence treatments aa. Tetracyclines
Public comment on single new drugs to be reviewed for the Medicaid PDL: a. Benlysta Autoinjector (subcutane) / Immunosuppressives b. Benlysta Syringe (subcutane) / Immunosuppressives c. Lumakras (oral) / Oncology, oral – lung d. Lupkynis (oral) / Immunosuppressives e. Truseltiq (oral) / Oncology, oral - other f. Zegalogue Autoinjector (subcutaneous) / Glucagon agents g. Zegalogue Syringe (subcutaneous) / Glucagon agents
Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
Executive work session Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
Retrospective drug utilization review (DUR): Conduent, LLC a. Recent interventions i. Caring for patients with dyslipidemia or at risk for coronary heart disease ii. Influenza prevention: vaccination and education b. Recent outcome reports i. Contraceptive drug use evaluation (DUE) c. Potential retrospective DUR interventions (vote required) i. Attention-deficit/hyperactivity disorder (ADHD) management ii. Opioids and central nervous system (CNS) depressants DUE
Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) a. Topical antifungal for treatment of onychomycosis – new criteria b. Antipsychotic agents i. Add Lybalvi - new criteria c. Cytokine and cell-adhesion molecule (CAM) i. Add Enspryng – new criteria d. Lupus – new criteria i. Benslysta (safety checks) ii. Lupknis (safety checks) e. SGLT2 i. Farxiga (revised criteria) ii. Jardiance (revised criteria)
Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) a. Atypical antipsychotics (long-acting injectable) b. Atypical antipsychotics (oral) c. Exogenous insulin products d. Nitazoxanide (Alinia®) e. Promethazine use in children less than 2 years of age f. Quetiapine (low dose)
Retrospective drug utilization review (DUR): Conduent, LLC a. Recent interventions i. Caring for patients with dyslipidemia or at risk for coronary heart disease ii. Influenza prevention: vaccination and education b. Recent outcome reports i. Contraceptive drug use evaluation (DUE) c. Potential retrospective DUR interventions (vote required) i. Attention-deficit/hyperactivity disorder (ADHD) management ii. Opioids and central nervous system (CNS) depressants DUE
11. Review of action and agenda items for next meeting: January 21, 2022 12. Adjournment
Call to order
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): (Part 1 of 2) a. Androgenic agents b. Antibiotics, gastrointestinal (GI) c. Antibiotics, topical d. Antibiotics, vaginal
Consideration of minutes from July 23, 2021 (vote required)
Public comment on the drug classes to be reviewed for the Medicaid Preferred Drug List (PDL): e. Anticonvulsants f. Antiemetics/Antivertigo agents g. Antifungals, oral h. Antifungals, topical i. Antihistamines - first generation j. Antiparasitics, topical k. Antipsychotics l. Antivirals, topical m. Bone resorption suppression and related agents n. Colony stimulating factors o. Epinephrine, self-injected p. GI Motility, chronic q. Growth hormone r. Hepatitis C s. HIV / AIDS t. Hypoglycemics, insulin and related agents u. Hypoglycemics, meglitinides v. Hypoglycemics, metformin w. Hypoglycemics, sodium-glucose cotransporter-2 (SGLT2) inhibitors x. Hypoglycemics, thiazolidinediones (TZDs) y. Macrolides-Ketolides z. Opiate dependence treatments aa. Tetracyclines
Public comment on single new drugs to be reviewed for the Medicaid PDL: a. Benlysta Autoinjector (subcutane) / Immunosuppressives b. Benlysta Syringe (subcutane) / Immunosuppressives c. Lumakras (oral) / Oncology, oral – lung d. Lupkynis (oral) / Immunosuppressives e. Truseltiq (oral) / Oncology, oral - other f. Zegalogue Autoinjector (subcutaneous) / Glucagon agents g. Zegalogue Syringe (subcutaneous) / Glucagon agents
Therapeutic and clinical drug reviews and updates: Magellan Medicaid Administration
Executive work session Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DURB may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
Announcements of drugs recommended for the Medicaid PDL: Magellan Medicaid Administration (vote required)
Retrospective drug utilization review (DUR): Conduent, LLC a. Recent interventions i. Caring for patients with dyslipidemia or at risk for coronary heart disease ii. Influenza prevention: vaccination and education b. Recent outcome reports i. Contraceptive drug use evaluation (DUE) c. Potential retrospective DUR interventions (vote required) i. Attention-deficit/hyperactivity disorder (ADHD) management ii. Opioids and central nervous system (CNS) depressants DUE
Prospective prior authorization proposals (clinical edits): KEPRO, LLC (vote required) a. Topical antifungal for treatment of onychomycosis – new criteria b. Antipsychotic agents i. Add Lybalvi - new criteria c. Cytokine and cell-adhesion molecule (CAM) i. Add Enspryng – new criteria d. Lupus – new criteria i. Benslysta (safety checks) ii. Lupknis (safety checks) e. SGLT2 i. Farxiga (revised criteria) ii. Jardiance (revised criteria)
Retrospective drug use criteria for outpatient use in Vendor Drug Program: The University of Texas at Austin College of Pharmacy (vote required) a. Atypical antipsychotics (long-acting injectable) b. Atypical antipsychotics (oral) c. Exogenous insulin products d. Nitazoxanide (Alinia®) e. Promethazine use in children less than 2 years of age f. Quetiapine (low dose)
Retrospective drug utilization review (DUR): Conduent, LLC a. Recent interventions i. Caring for patients with dyslipidemia or at risk for coronary heart disease ii. Influenza prevention: vaccination and education b. Recent outcome reports i. Contraceptive drug use evaluation (DUE) c. Potential retrospective DUR interventions (vote required) i. Attention-deficit/hyperactivity disorder (ADHD) management ii. Opioids and central nervous system (CNS) depressants DUE
11. Review of action and agenda items for next meeting: January 21, 2022 12. Adjournment